I bought this share @ 17 cents and had hold this share for a...

I bought this share @ 17 cents and had hold this share for a while , saw it's reaching .27 cents and i was hoping on CE mark approval it would reach 35 cents at least, so kept on holding. I bought it mostly due to its potential and believed in Daniel Kenny statements made at various investor interview that "CE mark is due soon and it's good time to be oncosil Investors". Unfortunately, it never pan out that way. Market lost confidence and due to lack of near term catalyst it shares started plummeting and i was kind of attached to this share, continued holding, thinking it would come back however it kept falling and i had to sell @ .12 cents, sustaining significant losses and not to mention it's psychological impact on me. I learned being emotionally attached to share wasn't good for me as i wasn't thinking objectively to interpret the things as they were. For example, delay for CE mark designation, board member composition, CEO credibility( what he said vs what happened), weak cash position, since everything got overshadowed by my optimism and greed for spectacular returns. These were clearly tell-tell sign that stocks will fall. However my greed fueled by other stock brokers valuation and my own optimism failed me. Nevertheless, holding this share was a great learning experience for me. I took this experience and invested my capital into other shares and turned into profit. It showed me there are other opportunities too. But, i still do believe it has potential and will provide spectacular returns however time frame to get return and risk associated with it is very high.
Furthermore, 21st century care Act might benefit oncosil product as it might lessen the regulatory approval time frame, allowing company to commercialise earlier.

Until and unless near term catalyst isn't there share will hover around 8 cents to 10 cents at best. Management knows that so they are trying to publish any information that is slightly positive. For example, today telling they have recruited first subject is positive especially for investors who are desperately waiting catalyst to bump up this share. But optimism aside, doesn't it question the capability of management to take this long to recruit one patient out of 20 patient. This news has two sides too. Lets be careful.